» Articles » PMID: 35814236

Optimizing Antimicrobial Therapy by Integrating Multi-Omics With Pharmacokinetic/Pharmacodynamic Models and Precision Dosing

Overview
Journal Front Pharmacol
Date 2022 Jul 11
PMID 35814236
Authors
Affiliations
Soon will be listed here.
Abstract

In the era of "," optimizing antibiotic therapy against multi-drug resistant (MDR) pathogens is crucial. Mathematical modelling has been employed to further optimize dosing regimens. These models include mechanism-based PK/PD models, systems-based models, quantitative systems pharmacology (QSP) and population PK models. Quantitative systems pharmacology has significant potential in precision antimicrobial chemotherapy in the clinic. Population PK models have been employed in model-informed precision dosing (MIPD). Several antibiotics require close monitoring and dose adjustments in order to ensure optimal outcomes in patients with infectious diseases. Success or failure of antibiotic therapy is dependent on the patient, antibiotic and bacterium. For some drugs, treatment responses vary greatly between individuals due to genotype and disease characteristics. Thus, for these drugs, tailored dosing is required for successful therapy. With antibiotics, inappropriate dosing such as insufficient dosing may put patients at risk of therapeutic failure which could lead to mortality. Conversely, doses that are too high could lead to toxicities. Hence, precision dosing which customizes doses to individual patients is crucial for antibiotics especially those with a narrow therapeutic index. In this review, we discuss the various strategies in optimizing antimicrobial therapy to address the challenges in the management of infectious diseases and delivering personalized therapy.

Citing Articles

The Evaluation of the Impact of Antibiotic De-escalation among Paediatric Patients Admitted to Tertiary Care Hospital in Ajman, UAE: A Cross-sectional Retrospective Observational Study.

Elshaeir N, Gillani S Curr Pediatr Rev. 2024; 21(1):67-74.

PMID: 39076090 DOI: 10.2174/0115733963283670240401075342.

References
1.
Zhang A, Gaston J, Dai C, Zhao S, Poyet M, Groussin M . An omics-based framework for assessing the health risk of antimicrobial resistance genes. Nat Commun. 2021; 12(1):4765. PMC: 8346589. DOI: 10.1038/s41467-021-25096-3. View

2.
Scheffler R, Colmer S, Tynan H, DEMAIN A, Gullo V . Antimicrobials, drug discovery, and genome mining. Appl Microbiol Biotechnol. 2012; 97(3):969-78. DOI: 10.1007/s00253-012-4609-8. View

3.
Kiratisin P, Chongthaleong A, Tan T, Lagamayo E, Roberts S, Garcia J . Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study. Int J Antimicrob Agents. 2012; 39(4):311-6. DOI: 10.1016/j.ijantimicag.2012.01.002. View

4.
Aminov R . History of antimicrobial drug discovery: Major classes and health impact. Biochem Pharmacol. 2016; 133:4-19. DOI: 10.1016/j.bcp.2016.10.001. View

5.
Erickson K, Otoupal P, Chatterjee A . Transcriptome-Level Signatures in Gene Expression and Gene Expression Variability during Bacterial Adaptive Evolution. mSphere. 2017; 2(1). PMC: 5311112. DOI: 10.1128/mSphere.00009-17. View